BOSTON & SAN JOSE, Calif.--(BUSINESS WIRE)--Corventis, Inc., a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions, announced today enrollment completion of the company’s MUSIC (Multi-Sensor Monitoring in Congestive Heart Failure) program consisting of 2 trials: the MUSIC Asia (180 patients) and the pivotal MUSIC study (362 patients). The MUSIC program – the goal of which is to develop and evaluate an algorithm to predict heart failure events – has enrolled a total of 542 patients in the international, multi-center prospective trials. Preliminary findings from the MUSIC Asia study were presented today at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston, Mass.
